Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies

Frontiers in Immunology

Immunology

Min Zhou¹  Yongjiang Li¹  Xinyan Hao¹  Wenjie Xu¹  Yucheng Tang¹  Si Huang¹  Daxiong Xiang¹  Junyong Wu² 

[1] Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China;Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China;Institute of Clinical Pharmacy, Central South University, Changsha, China;Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China;Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha, China;Institute of Clinical Pharmacy, Central South University, Changsha, China;Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Changsha, China;

关键词: bacteria;    immunotherapy;    cancer;    tumor model;    vaccine;    colonization;   

DOI  :  10.3389/fimmu.2023.1140463

 received in 2023-01-09, accepted in 2023-03-30,  发布年份 2023

来源: Frontiers

【 摘 要 】

Immunotherapy has been emerging as a powerful strategy for cancer management. Recently, accumulating evidence has demonstrated that bacteria-based immunotherapy including naive bacteria, bacterial components, and bacterial derivatives, can modulate immune response via various cellular and molecular pathways. The key mechanisms of bacterial antitumor immunity include inducing immune cells to kill tumor cells directly or reverse the immunosuppressive microenvironment. Currently, bacterial antigens synthesized as vaccine candidates by bioengineering technology are novel antitumor immunotherapy. Especially the combination therapy of bacterial vaccine with conventional therapies may further achieve enhanced therapeutic benefits against cancers. However, the clinical translation of bacteria-based immunotherapy is limited for biosafety concerns and non-uniform production standards. In this review, we aim to summarize immunotherapy strategies based on advanced bacterial therapeutics and discuss their potential for cancer management, we will also propose approaches for optimizing bacteria-based immunotherapy for facilitating clinical translation.

【 授权许可】

Unknown   
Copyright © 2023 Zhou, Tang, Xu, Hao, Li, Huang, Xiang and Wu